meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
versus all
vs non active control
vs placebo
All patients
Age < 65y (younger)
Age > 65y
Asian type
cancer location (esophagus)
cancer location (gastro-esophageal)
cell type, adenocarcinoma cell
cell type, squamous cell
ECOG 0
ECOG 1
Gender, female
Gender, male
HER2 negative
HER2 positive
PD-L1 < 1%
PD-L1 > 1%
stage II
stage III (locally advanced)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
events or deaths (EFS)
AE (any grade)
AE (grade 3-4)
AE leading to treatment discontinuation (any grade)
AE leading to treatment discontinuation (grade 3-4)
SAE (any grade)
SAE (grade 3-4)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
events or deaths (EFS)
mEC - (neo)adjuvant (NA)
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
versus placebo
nivolumab alone vs. placebo
1
0.63
[0.46; 0.86], 1 RCT, I2=0%
conclusive
unassessable degree of certainty
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open